Nuvation Bio
38 articles about Nuvation Bio
-
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
4/10/2024
Nuvation Bio Inc. (NYSE: NUVB) today announced the completion of the acquisition of AnHeart Therapeutics Ltd. (AnHeart), a late-stage, global biopharmaceutical company developing novel precision therapies for people with cancer.
-
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
3/28/2024
Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced the appointment of Colleen Sjogren as Chief Commercial Officer.
-
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
3/25/2024
Nuvation Bio Inc. and AnHeart Therapeutics Ltd. today announced that the companies have entered into a definitive agreement for Nuvation Bio to acquire AnHeart in an all-stock transaction (the Acquisition).
-
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
3/14/2024
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the first patient has been dosed in a Phase 1/2 study of NUV-1511, the Company’s first DDC to enter the clinic.
-
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/29/2024
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
-
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors
1/8/2024
Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced the appointment of Robert Mashal, M.D. to its Board of Directors.
-
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
1/8/2024
Nuvation Bio Inc. (NYSE: NUVB) announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate NUV-1511, the first clinical candidate from the company’s novel drug-drug conjugate (DDC) platform.
-
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
11/2/2023
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the third quarter ended September 30, 2023, and provided a business update.
-
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
8/3/2023
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2023, and provided a business update.
-
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board
6/1/2023
Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced the formation of a Scientific Advisory Board.
-
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update
5/4/2023
Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, reported its financial results for the first quarter ended March 31, 2023, and provided a business update.
-
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/15/2023
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.
-
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
12/19/2022
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced it has dosed the first patient in a Phase 1b study of its BD2-selective BET inhibitor, NUV-868, in combination with olaparib.
-
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
11/3/2022
Nuvation Bio Inc. today reported its financial results for the third quarter ended September 30, 2022, and provided a business update.
-
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
8/4/2022
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2022, and provided a business update.
-
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
8/1/2022
Nuvation Bio Inc. today announced that it will prioritize NUV-868 and development of its novel small molecule DDC platform and discontinue clinical development of NUV-422.
-
The decision comes after the FDA put NUV-422, its candidate for high-grade gliomas, on a partial clinical hold, citing safety concerns.
-
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer
7/18/2022
Nuvation Bio Inc. today announced the appointment of David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer.
-
Monday morning, Nuvation Bio announced that the U.S. Food and Drug Administration placed a partial clinical hold on its Phase I dose escalation study of NUV-422.
-
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors
6/27/2022
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the Food and Drug Administration (FDA) has placed a partial clinical hold on the Company’s Phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer.